References
J.P. Bilezikian, M.L. Brandi, M. Rubin, S.J. Silverberg, Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J. Intern. Med. 257(1), 6–17 (2005). doi:10.1111/j.1365-2796.2004.01422.x
S.J. Silverberg, E. Shane, T.P. Jacobs, E. Siris, J.P. Bilezikian, A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341(17), 1249–1255 (1999). doi:10.1056/NEJM199910213411701
M.R. Rubin, J.P. Bilezikian, D.J. McMahon, T. Jacobs, E. Shane, E. Siris, J. Udesky, S.J. Silverberg, The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metab. 93(9), 3462–3470 (2008). doi:10.1210/jc.2007-1215
R. Eastell, A. Arnold, M.L. Brandi, E.M. Brown, P. D’Amour, D.A. Hanley, D.S. Rao, M.R. Rubin, D. Goltzman, S.J. Silverberg, S.J. Marx, M. Peacock, L. Mosekilde, R. Bouillon, E.M. Lewiecki, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009). doi:10.1210/jc.2008-1758
J.P. Bilezikian, A.A. Khan, J.T. Potts Jr, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 335–339 (2009). doi:10.1210/jc.2008-1763
E.F. Nemeth, W.H. Heaton, M. Miller, J. Fox, M.F. Balandrin, B.C. Van Wagenen, M. Colloton, W. Karbon, J. Scherrer, E. Shatzen, G. Rishton, S. Scully, M. Qi, R. Harris, D. Lacey, D. Martin, Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308(2), 627–635 (2004). doi:10.1124/jpet.103.057273
C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M.E. Rodriguez, S. Canadillas, A. Martin-Malo, P. Aljama, Cinacalcet reduces the set point of the PTH-calcium curve. J. Am. Soc. Nephrol. 19(12), 2430–2436 (2008). doi:10.1681/ASN.2007121320
N. Verheyen, S. Pilz, K. Eller, K. Kienreich, A. Fahrleitner-Pammer, B. Pieske, E. Ritz, A. Tomaschitz, Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opin. Pharmacother. 14(6), 793–806 (2013). doi:10.1517/14656566.2013.777041
M.H. Gault, L.L. Longerich, J.D. Harnett, C. Wesolowski, Predicting glomerular function from adjusted serum creatinine. Nephron 62(3), 249–256 (1992)
H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137–1148 (1993). doi:10.1002/jbmr.5650080915
A.A. Khan, J.P. Bilezikian, A.W. Kung, M.M. Ahmed, S.J. Dubois, A.Y. Ho, D. Schussheim, M.R. Rubin, A.M. Shaikh, S.J. Silverberg, T.I. Standish, Z. Syed, Z.A. Syed, Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89(7), 3319–3325 (2004). doi:10.1210/jc.2003-03090889/7/3319
A. Khan, A. Grey, D. Shoback, Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 373–381 (2009). doi:10.1210/jc.2008-1762
M. Peacock, J.P. Bilezikian, M.A. Bolognese, M. Borofsky, S. Scumpia, L.R. Sterling, S. Cheng, D. Shoback, Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab. 96(1), E9–E18 (2011). doi:10.1210/jc.2010-1221
M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells Jr, S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001). doi:10.1210/jcem.86.12.8070
N. Yu, G.P. Leese, D. Smith, P.T. Donnan, The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM 104(6), 513–521 (2011). doi:10.1093/qjmed/hcq261
S. Corbetta, G. Mantovani, A. Lania, S. Borgato, L. Vicentini, E. Beretta, G. Faglia, A.M. Di Blasio, A. Spada, Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia. Clin Endocrinol 52(3), 339–348 (2000)
J. Gogusev, P. Duchambon, B. Hory, M. Giovannini, Y. Goureau, E. Sarfati, T.B. Drueke, Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51(1), 328–336 (1997)
C.A. Frolik, E.C. Black, R.L. Cain, J.H. Satterwhite, P.L. Brown-Augsburger, M. Sato, J.M. Hock, Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33(3), 372–379 (2003)
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. Nothing to declare about financial disclosure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marotta, V., Di Somma, C., Rubino, M. et al. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. Endocrine 49, 274–278 (2015). https://doi.org/10.1007/s12020-014-0381-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0381-0